S. Z. Wu

Systematic perturbation screens decode regulators of inflammatory macrophage states and identify a role for TNF mRNA m6A modification

The paper identifies regulators of inflammatory macrophage states and shows that TNF mRNA m6A modification controls its stability and contributes to disease.

Integration of single-cell RNA and protein data identifies novel clinically-relevant lymphocyte phenotypes in breast cancers

The paper integrates single-cell RNA and protein data from breast cancer samples to identify novel lymphocyte phenotypes and their clinical relevance.

DNA barcoding reveals ongoing immunoediting of clonal cancer populations during metastatic progression and in response to immunotherapy

This study uses DNA barcoding to track clonal evolution in breast cancer during metastasis and immunotherapy, finding ongoing immunoediting and identifying potential therapeutic targets.

Spatial Deconvolution of HER2-positive Breast Tumors Reveals Novel Intercellular Relationships

This study uses spatial transcriptomics to analyze HER2-positive breast tumors, revealing novel intercellular relationships and developing a model for tertiary lymphoid structures across tissues.

Single-cell analysis reveals diverse stromal subsets associated with immune evasion in triple-negative breast cancer

This study identifies diverse stromal subsets in TNBC using single-cell RNA-seq and links them to immune evasion mechanisms and therapeutic targets.

Cryopreservation of human cancers conserves tumour heterogeneity for single-cell multi-omics analysis

This study shows that cryopreservation of human cancers preserves tumour heterogeneity for single-cell multi-omics analysis, with comparable results to fresh tissue.

Targeting stromal remodeling and cancer stem cell plasticity to overcome chemoresistance in triple negative breast cancer

This study identifies Hedgehog signaling to cancer-associated fibroblasts as a driver of cancer stem cell plasticity and chemoresistance in TNBC, showing that targeting this pathway with smoothened inhibitors improves survival in preclinical models and clinical trials.